Glycomine, Inc., Corporation just released form D regarding $12.64 million equity financing. This is a new filing. Glycomine was able to fundraise $4.93 million so far. That is 39.03% of the financing offer. The total private offering amount was $12.64 million. The financing document was filed on 2016-11-10. The reason for the financing was: Remainder to be sold is subject to satisfaction of certain milestones.. The fundraising still has about $7.71 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Glycomine is based in California. The firm’s business is Biotechnology. The SEC form was filed by Andrew Dick Authorized Person. The company was incorporated in 2014. The filler’s address is: 953 Indiana Street, San Francisco, Ca, California, 94107. Agnes Rafalko is the related person in the form and it has address: C/O Glycomine, Inc., 953 Indiana Street, San Francisco, Ca, California, 94107. Link to Glycomine Filing: 000168979216000001.
Analysis of Glycomine Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Glycomine sold 39.03% of the offering. The fundraising is still open. The average fundraising amount for companies in the Biotechnology industry is $3.08 million. The total amount raised is 60.21% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing is set at $10000. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Glycomine Also
The Form D signed by Andrew Dick might help Glycomine, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.